The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease

Thyroid Eye Disease (TED) is a vision threatening condition caused by inflammatory damage to the periocular tissue. Teprotumumab is an IGF-1R antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated regarding its effects on diplopia outcomes among TED patients. Diplopia is a significant and life altering effect of TED. Prior studies have reported teprotumumab's effect on double vision subjectively using the Gorman diplopia score. However, there is a gap in the literature addressing the effect of teprotumumab treatment on objective ocular alignment measures, and this is what we aim to address